Product Information
AZELASTIN-FLUTIC 137-50 MCG SPR is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $2.0210 per GM under NDC 45802006601. Its NADAC has been published 283 times since May 5, 2021.
FDA first approved this application on Feb 18, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
137; 50 ug/1; ug/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802006601
Classification
Generic
Dosage Form
SPRAY, METERED
Route
NASAL
Effective Date
9/23/2026
Active Ingredients
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATEApproval Type
Generic (ANDA)
FDA Application
ANDA208111FDA Approved
2/18/2021
TE Code
AB
On Market Since
3/1/2021
Pharmacological Classes
Price Statistics
The NADAC for AZELASTIN-FLUTIC 137-50 MCG SPR has been published 283 times since May 5, 2021, and over the history we have for it it has declined 63.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.0210 per GM |
|---|---|
| All-time high | $5.5637 (May 12, 2021) |
| All-time low | $2.0210 (Sep 23, 2026) |
| 52-week high | $3.1882 |
| 52-week low | $2.0210 |
| Median price | $3.2816 |
| Average price | $3.5001 |
| Largest weekly change | +16.0% (Dec 22, 2021) |
| Weeks tracked | 283 |
| Tracking since | May 5, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the azelastine hydrochloride, fluticasone propionate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
azelastine hydrochloride, fluticasone propionate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AZELASTIN-FLUTIC 137-50 MCG SPR?
The current National Average Drug Acquisition Cost (NADAC) for AZELASTIN-FLUTIC 137-50 MCG SPR, manufactured by Padagis Israel Pharmaceuticals Ltd, is $2.0210 per GM (NDC 45802006601), effective Sep 30, 2026.
How has the price of AZELASTIN-FLUTIC 137-50 MCG SPR changed over time?
Over the history we have for it, the NADAC for AZELASTIN-FLUTIC 137-50 MCG SPR has declined 63.7%. It has been tracked across 283 weekly CMS publications since May 5, 2021.
What are the highest and lowest recorded NADAC prices for AZELASTIN-FLUTIC 137-50 MCG SPR?
Since May 5, 2021, the NADAC for AZELASTIN-FLUTIC 137-50 MCG SPR has ranged from a low of $2.0210 (Sep 23, 2026) to a high of $5.5637 (May 12, 2021), with a median of $3.2816 per GM.
Are there cheaper alternatives to AZELASTIN-FLUTIC 137-50 MCG SPR?
No other NADAC-published product currently shares the active ingredient and strength of AZELASTIN-FLUTIC 137-50 MCG SPR in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AZELASTIN-FLUTIC 137-50 MCG SPR?
AZELASTIN-FLUTIC 137-50 MCG SPR (NDC 45802006601) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.